SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-019870
Filing Date
2022-04-14
Accepted
2022-04-14 16:58:19
Documents
12
Period of Report
2022-04-14

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea158402-6k_nlspharma.htm 6-K 33478
2 FORM OF COMMON WARRANT ea158402ex4-1_nlspharma.htm EX-4.1 87809
3 FORM OF PRE-FUNDED WARRANT ea158402ex4-2_nlspharma.htm EX-4.2 79808
4 OPINION OF WENGER VIELI AG, SWISS COUNSEL TO NLS PHARMACEUTICS LTD ea158402ex5-1_nlspharma.htm EX-5.1 27322
5 OPINION OF SULLIVAN & WORCESTER LLP, U.S. COUNSEL TO NLS PHARMACEUTICS LTD ea158402ex5-2_nlspharma.htm EX-5.2 13720
6 FORM OF SECURITIES PURCHASE AGREEMENT, DATED APRIL 13, 2022, BY AND BETWEEN NLS ea158402ex10-1_nlspharma.htm EX-10.1 264308
7 PLACEMENT AGENT AGREEMENT, DATED APRIL 13, 2022, BY AND BETWEEN NLS PHARMACEUTIC ea158402ex10-2_nlspharma.htm EX-10.2 54276
8 PRESS RELEASE ea158402ex99-1_nlspharma.htm EX-99.1 14301
9 GRAPHIC ex5-1_001.jpg GRAPHIC 3283
10 GRAPHIC ex5-2_001.jpg GRAPHIC 6070
11 GRAPHIC ex5-2_002.jpg GRAPHIC 5947
12 GRAPHIC ex99-1_001.jpg GRAPHIC 4418
  Complete submission text file 0001213900-22-019870.txt   603743
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 22828017
SIC: 2834 Pharmaceutical Preparations